Chronic murine paracoccidioidomycosis: effect of ketoconazole on clearance of Paracoccidioides brasiliensis and immune response.
In a murine model of chronic pulmonary and disseminated paracoccidioidomycosis, ketoconazole (100 mg kg-1 in 0.3% agar) given by gavage twice daily for 1 or 2 months enabled all mice to clear disseminated Paracoccidioides brasiliensis from the spleen. Clearance of P. brasiliensis from the lungs was more difficult, and was achieved in 60% of the mice treated for 2 months. Sera from agar-treated control mice at days 77 and 103 post-infection demonstrated precipitating antibodies to P. brasiliensis antigens, but sera from ketoconazole-treated mice were precipitin-negative, indicating a favorable prognosis. Delayed hypersensitivity reactions to P. brasiliensis antigens in ketoconazole-treated mice were not significantly greater than in controls; consequently this test correlated less well with response than levels of serum antibody. This is the first use of this animal model of paracoccidioidomycosis to study the effect of antifungal drug protocols on the resolution of the disease. It also demonstrates the utility of this model in addressing clinically relevant questions about this disease and its treatment.
D000818:Animals; D000908:Antibodies, Fungal / Q000096:biosynthesis; D002908:Chronic Disease; D004195:Disease Models, Animal; D005658:Fungi / Q000187:drug effects*; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007654:Ketoconazole / Q000494:pharmacology*; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010228:Paracoccidioides / Q000187:drug effects* / Q000276:immunology / Q000302:isolation & purification; D010229:Paracoccidioidomycosis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D013154:Spleen / Q000382:microbiology
D000908:Antibodies, Fungal; D007654:Ketoconazole